Yi Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yi Zhang has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
Ying Wang
Center for Discovery and Innovation, Hackensack University Medical Center, Hackensack Meridian Health, Nutley, USA
7 shared publicationsYuanyuan Tian
Center for Discovery and Innovation, Hackensack University Medical Center, Hackensack Meridian Health, Nutley, USA
7 shared publicationsLijun Meng
Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA, 19140, USA
5 shared publicationsCiril Abraham
Center for Discovery and Innovation, Hackensack Meridian Health, Hackensack Meridian School of Medicine, Nutley, New Jersey 07110, United States
4 shared publications- Shaoyan Hu
Department of Hematology, Jiangsu Children’s Hematology and Oncology Center, and the Children’s Hospital of Soochow University, Suzhou, China
4 shared publications Yongnian Liu
Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA, 19140, USA
4 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (7) , 840-854
EZH2 and intracellular Ca2+ signals interdependently coordinate alloreactive and CAR-T-cell responses
In graft-versus-host disease (GVHD), Ca 2+ signals in alloreactive T cells are carefully controlled to determine whether cells survive or thrive, although how this is accomplished during GVHD remains poorly defined. We demonstrate that EZH2, a chromatin-modifying enzyme, promotes alloreactive T-cell survival in GVHD by acting as a Ca 2+ signaling brake to limit excessive intracellular Ca 2+ responses. Ezh2 loss led to the upregulation of gene programs that promote effector differentiation in activated T cells, coincident with enhanced intracellular Ca 2+ responses that ultimately caused massive cell death. Conditional deletion of Stim1 (required for cytosolic Ca 2+ entry) led to “synthetic rescue” of Ezh2 -null T cells by protecting them from cell death without interfering with effector differentiation, resulting in severe GVHD. Interestingly, Stim1 expression was unaffected by EZH2, whereas the expression of the endoplasmic reticulum Ca 2+ release channel inositol 1,4,5-trisphosphate receptor 2 ( Itpr2 ) was suppressed by EZH2. Notably, EZH2 and Ca 2+ signals served mutually opposing roles in controlling the expression of genes in chimeric antigen receptor (CAR) T cells. Inhibiting Ca²⁺ signaling restored EZH2 function in CAR-T cells, significantly improving their antitumor activity. Our findings reveal the interdependent roles of EZH2 and Ca 2+ signals in coordinating antigen-activated T-cell responses that mediate alloimmunity and tumor immunity.
- 22 April 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (7) , 840-854
Open AccessEZH2 and intracellular Ca2+ signals interdependently coordinate alloreactive and CAR-T-cell responses
In graft-versus-host disease (GVHD), Ca 2+ signals in alloreactive T cells are carefully controlled to determine whether cells survive or thrive, although how this is accomplished during GVHD remains poorly defined. We demonstrate that EZH2, a chromatin-modifying enzyme, promotes alloreactive T-cell survival in GVHD by acting as a Ca 2+ signaling brake to limit excessive intracellular Ca 2+ responses. Ezh2 loss led to the upregulation of gene programs that promote effector differentiation in activated T cells, coincident with enhanced intracellular Ca 2+ responses that ultimately caused massive cell death. Conditional deletion of Stim1 (required for cytosolic Ca 2+ entry) led to “synthetic rescue” of Ezh2 -null T cells by protecting them from cell death without interfering with effector differentiation, resulting in severe GVHD. Interestingly, Stim1 expression was unaffected by EZH2, whereas the expression of the endoplasmic reticulum Ca 2+ release channel inositol 1,4,5-trisphosphate receptor 2 ( Itpr2 ) was suppressed by EZH2. Notably, EZH2 and Ca 2+ signals served mutually opposing roles in controlling the expression of genes in chimeric antigen receptor (CAR) T cells. Inhibiting Ca²⁺ signaling restored EZH2 function in CAR-T cells, significantly improving their antitumor activity. Our findings reveal the interdependent roles of EZH2 and Ca 2+ signals in coordinating antigen-activated T-cell responses that mediate alloimmunity and tumor immunity.
- 15 November 2025
- Published by Elsevier in Molecular Therapy
- Vol. 34 (2) , 898-915
Engineered suppressor T cells overexpressing IFN-α and PD-L1 inhibit GVHD but retain GVL effects in mice
- 15 November 2025
- Published by Elsevier in Molecular Therapy
- Vol. 34 (2) , 898-915
Engineered suppressor T cells overexpressing IFN-α and PD-L1 inhibit GVHD but retain GVL effects in mice
- 11 January 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (2) , 166-177
Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD
Persisting alloreactive donor T cells in target tissues are a determinant of graft-versus-host disease (GVHD), but the transcriptional regulators that control the persistence and function of tissue-infiltrating T cells remain elusive. We demonstrate here that Id3, a DNA-binding inhibitor, is critical for sustaining T-cell responses in GVHD target tissues in mice, including the liver and intestine. Id3 loss results in aberrantly expressed PD-1 in polyfunctional T helper 1 (Th1) cells, decreased tissue-infiltrating PD-1+ polyfunctional Th1 cell numbers, impaired maintenance of liver TCF-1+ progenitor-like T cells, and inhibition of GVHD. PD-1 blockade restores the capacity of Id3-ablated donor T cells to mediate GVHD. Single-cell RNA-sequencing analysis revealed that Id3 loss leads to significantly decreased CD28- and PI3K/AKT-signaling activity in tissue-infiltrating polyfunctional Th1 cells, an indicator of active PD-1/PD-L1 effects. Id3 is also required for protecting CD8+ T cells from the PD-1 pathway–mediated suppression during GVHD. Genome-wide RNA-sequencing analysis reveals that Id3 represses transcription factors (e.g., Nfatc2, Fos, Jun, Ets1, and Prdm1) that are critical for PD-1 transcription, exuberant effector differentiation, and interferon responses and dysfunction of activated T cells. Id3 achieves these effects by restraining the chromatin accessibility for these transcription factors. Id3 ablation in donor T cells preserved their graft vs tumor effects in mice undergoing allogeneic hematopoietic stem cell transplantation. Furthermore, CRISPR/Cas9 knockout of ID3 in human CD19–directed chimeric antigen receptor T cells retained their antitumor activity in NOD/SCID/IL2Rg−/− mice early after administration. These findings identify that ID3 is an important target to reduce GVHD, and the gene-editing program of ID3 may have broad implications in T-cell–based immunotherapy.
- 11 January 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (2) , 166-177
Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD
Persisting alloreactive donor T cells in target tissues are a determinant of graft-versus-host disease (GVHD), but the transcriptional regulators that control the persistence and function of tissue-infiltrating T cells remain elusive. We demonstrate here that Id3, a DNA-binding inhibitor, is critical for sustaining T-cell responses in GVHD target tissues in mice, including the liver and intestine. Id3 loss results in aberrantly expressed PD-1 in polyfunctional T helper 1 (Th1) cells, decreased tissue-infiltrating PD-1+ polyfunctional Th1 cell numbers, impaired maintenance of liver TCF-1+ progenitor-like T cells, and inhibition of GVHD. PD-1 blockade restores the capacity of Id3-ablated donor T cells to mediate GVHD. Single-cell RNA-sequencing analysis revealed that Id3 loss leads to significantly decreased CD28- and PI3K/AKT-signaling activity in tissue-infiltrating polyfunctional Th1 cells, an indicator of active PD-1/PD-L1 effects. Id3 is also required for protecting CD8+ T cells from the PD-1 pathway–mediated suppression during GVHD. Genome-wide RNA-sequencing analysis reveals that Id3 represses transcription factors (e.g., Nfatc2, Fos, Jun, Ets1, and Prdm1) that are critical for PD-1 transcription, exuberant effector differentiation, and interferon responses and dysfunction of activated T cells. Id3 achieves these effects by restraining the chromatin accessibility for these transcription factors. Id3 ablation in donor T cells preserved their graft vs tumor effects in mice undergoing allogeneic hematopoietic stem cell transplantation. Furthermore, CRISPR/Cas9 knockout of ID3 in human CD19–directed chimeric antigen receptor T cells retained their antitumor activity in NOD/SCID/IL2Rg−/− mice early after administration. These findings identify that ID3 is an important target to reduce GVHD, and the gene-editing program of ID3 may have broad implications in T-cell–based immunotherapy.
- Open Access
- 18 September 2023
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (21) , e113975
Infection and inflammation stimulate expansion of a CD74+ Paneth cell subset to regulate disease progression
Paneth cells (PCs), a specialized secretory cell type in the small intestine, are increasingly recognized as having an essential role in host responses to microbiome and environmental stresses. Whether and how commensal and pathogenic microbes modify PC composition to modulate inflammation remain unclear. Using newly developed PC-reporter mice under conventional and gnotobiotic conditions, we determined PC transcriptomic heterogeneity in response to commensal and invasive microbes at single cell level. Infection expands the pool of CD74+ PCs, whose number correlates with auto or allogeneic inflammatory disease progressions in mice. Similar correlation was found in human inflammatory disease tissues. Infection-stimulated cytokines increase production of reactive oxygen species (ROS) and expression of a PC-specific mucosal pentraxin (Mptx2) in activated PCs. A PC-specific ablation of MyD88 reduced CD74+ PC population, thus ameliorating pathogen-induced systemic disease. A similar phenotype was also observed in mice lacking Mptx2. Thus, infection stimulates expansion of a PC subset that influences disease progression.
- 18 September 2023
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (21) , e113975
Open AccessInfection and inflammation stimulate expansion of a CD74+ Paneth cell subset to regulate disease progression
Paneth cells (PCs), a specialized secretory cell type in the small intestine, are increasingly recognized as having an essential role in host responses to microbiome and environmental stresses. Whether and how commensal and pathogenic microbes modify PC composition to modulate inflammation remain unclear. Using newly developed PC-reporter mice under conventional and gnotobiotic conditions, we determined PC transcriptomic heterogeneity in response to commensal and invasive microbes at single cell level. Infection expands the pool of CD74+ PCs, whose number correlates with auto or allogeneic inflammatory disease progressions in mice. Similar correlation was found in human inflammatory disease tissues. Infection-stimulated cytokines increase production of reactive oxygen species (ROS) and expression of a PC-specific mucosal pentraxin (Mptx2) in activated PCs. A PC-specific ablation of MyD88 reduced CD74+ PC population, thus ameliorating pathogen-induced systemic disease. A similar phenotype was also observed in mice lacking Mptx2. Thus, infection stimulates expansion of a PC subset that influences disease progression.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts
Supplemental Table S1. Primers for real-time RT-PCR
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts
Supplemental Table S1. Primers for real-time RT-PCR
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts
Supplemental Table S1. Primers for real-time RT-PCR
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts
Supplemental Table S1. Primers for real-time RT-PCR
- Open Access
- 2 March 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (9) , 1070-1086
A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis
Intestinal epithelial cells (IECs) are implicated in the propagation of T-cell–mediated inflammatory diseases, including graft-versus-host disease (GVHD), but the underlying mechanism remains poorly defined. Here, we report that IECs require receptor-interacting protein kinase-3 (RIPK3) to drive both gastrointestinal (GI) tract and systemic GVHD after allogeneic hematopoietic stem cell transplantation. Selectively inhibiting RIPK3 in IECs markedly reduces GVHD in murine intestine and liver. IEC RIPK3 cooperates with RIPK1 to trigger mixed lineage kinase domain-like protein-independent production of T-cell–recruiting chemokines and major histocompatibility complex (MHC) class II molecules, which amplify and sustain alloreactive T-cell responses. Alloreactive T-cell–produced interferon gamma enhances this RIPK1/RIPK3 action in IECs through a JAK/STAT1-dependent mechanism, creating a feed-forward inflammatory cascade. RIPK1/RIPK3 forms a complex with JAK1 to promote STAT1 activation in IECs. The RIPK1/RIPK3-mediated inflammatory cascade of alloreactive T-cell responses results in intestinal tissue damage, converting the local inflammation into a systemic syndrome. Human patients with severe GVHD showed highly activated RIPK1 in the colon epithelium. Finally, we discover a selective and potent RIPK1 inhibitor (Zharp1-211) that significantly reduces JAK/STAT1-mediated expression of chemokines and MHC class II molecules in IECs, restores intestinal homeostasis, and arrests GVHD without compromising the graft-versus-leukemia (GVL) effect. Thus, targeting RIPK1/RIPK3 in IECs represents an effective nonimmunosuppressive strategy for GVHD treatment and potentially for other diseases involving GI tract inflammation.
- 2 March 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (9) , 1070-1086
Open AccessA novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis
Intestinal epithelial cells (IECs) are implicated in the propagation of T-cell–mediated inflammatory diseases, including graft-versus-host disease (GVHD), but the underlying mechanism remains poorly defined. Here, we report that IECs require receptor-interacting protein kinase-3 (RIPK3) to drive both gastrointestinal (GI) tract and systemic GVHD after allogeneic hematopoietic stem cell transplantation. Selectively inhibiting RIPK3 in IECs markedly reduces GVHD in murine intestine and liver. IEC RIPK3 cooperates with RIPK1 to trigger mixed lineage kinase domain-like protein-independent production of T-cell–recruiting chemokines and major histocompatibility complex (MHC) class II molecules, which amplify and sustain alloreactive T-cell responses. Alloreactive T-cell–produced interferon gamma enhances this RIPK1/RIPK3 action in IECs through a JAK/STAT1-dependent mechanism, creating a feed-forward inflammatory cascade. RIPK1/RIPK3 forms a complex with JAK1 to promote STAT1 activation in IECs. The RIPK1/RIPK3-mediated inflammatory cascade of alloreactive T-cell responses results in intestinal tissue damage, converting the local inflammation into a systemic syndrome. Human patients with severe GVHD showed highly activated RIPK1 in the colon epithelium. Finally, we discover a selective and potent RIPK1 inhibitor (Zharp1-211) that significantly reduces JAK/STAT1-mediated expression of chemokines and MHC class II molecules in IECs, restores intestinal homeostasis, and arrests GVHD without compromising the graft-versus-leukemia (GVL) effect. Thus, targeting RIPK1/RIPK3 in IECs represents an effective nonimmunosuppressive strategy for GVHD treatment and potentially for other diseases involving GI tract inflammation.
- 21 October 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (6) , 837-845
The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy
EZH2 is a histone methyltransferase. It catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3) to control gene transcription critical for cell proliferation, differentiation, expansion, and function. For instance, EZH2 plays a central role in regulating T-cell immune responses. EZH2 restrains terminal differentiation of effector CD8 T cells, promotes formation of precursor and mature memory CD8 T cells, regulates appropriate lineage-specification and identity maintenance of helper CD4 T cells, and maintains survival of differentiated antigen-specific T cells. Most importantly, EZH2 is shown to be important for reinvigoration of exhausted chimeric antigen receptor (CAR) T cells. Dysregulated EZH2 function has been linked to many forms of cancer, including lymphomas and solid tumors. In B-cell lymphoid malignancies, EZH2 is overexpressed to drive tumorigenesis. These specific effects of EZH2, in the context of its roles in catalyzing H3K27me3 and orchestrating gene transcription programs in both normal and malignant cells, establishes EZH2 as a unique target for drug development. Here, we will discuss Ezh2 regulation of T-cell immunity, EZH2-mediated lymphomagenesis, and therapeutic benefits of EZH2 inhibitors to the treatment of lymphoma.
- 21 October 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (6) , 837-845
The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy
EZH2 is a histone methyltransferase. It catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3) to control gene transcription critical for cell proliferation, differentiation, expansion, and function. For instance, EZH2 plays a central role in regulating T-cell immune responses. EZH2 restrains terminal differentiation of effector CD8 T cells, promotes formation of precursor and mature memory CD8 T cells, regulates appropriate lineage-specification and identity maintenance of helper CD4 T cells, and maintains survival of differentiated antigen-specific T cells. Most importantly, EZH2 is shown to be important for reinvigoration of exhausted chimeric antigen receptor (CAR) T cells. Dysregulated EZH2 function has been linked to many forms of cancer, including lymphomas and solid tumors. In B-cell lymphoid malignancies, EZH2 is overexpressed to drive tumorigenesis. These specific effects of EZH2, in the context of its roles in catalyzing H3K27me3 and orchestrating gene transcription programs in both normal and malignant cells, establishes EZH2 as a unique target for drug development. Here, we will discuss Ezh2 regulation of T-cell immunity, EZH2-mediated lymphomagenesis, and therapeutic benefits of EZH2 inhibitors to the treatment of lymphoma.
- Open Access
- 22 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (43)
Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
With a well-defined mechanism, spike nanoparticles offer an effective vaccine solution to SARS-CoV-2 variants.
- 22 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (43)
Open AccessMechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants
With a well-defined mechanism, spike nanoparticles offer an effective vaccine solution to SARS-CoV-2 variants.
- Open Access
- 8 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (41)
Leukemic progenitor cells enable immunosuppression and post-chemotherapy relapse via IL-36–inflammatory monocyte axis
A stimulated proinflammatory feature of leukemic progenitors facilitates their survival and immune evasion after chemotherapy.
- 8 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (41)
Open AccessLeukemic progenitor cells enable immunosuppression and post-chemotherapy relapse via IL-36–inflammatory monocyte axis
A stimulated proinflammatory feature of leukemic progenitors facilitates their survival and immune evasion after chemotherapy.